Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)

NCT05997810 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05997810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05997810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)
Lead sponsor
Washington University School of Medicine
Phase
Observational
Overall status
Recruiting
Start date
July 28, 2023
Completion date
January 31, 2032
Enrollment
839 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parathyroid tumor, primary hyperparathyroidism, secondary hyperparathyroidism (shpt), tertiary hyperparathyroidism